Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia June 9, 2026 health-equity ONLY AVAILABLE IN PAID PLANS. Originally reported by biospace. Read more Source: https://www.biospace.com/press-releases/bausch-health-canada-inc-and-the-pan-canadian-pharmaceutical-alliance-sign-letter-of-intent-for-public-drug-plan-coverage-of-prokedi-risperidone-for-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia
